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News in Brief

Those Who Give

Survivor Turned
Supporter
Diagnosed with and successfully
treated for breast cancer at Jefferson
in 1984, Marianne Connolly
returned when faced with a potential
diagnosis of pancreatic cancer in
2005. Feeling blessed by her
fortunate outcome and access to
excellent medical care, Marianne
and her husband Charles made a
very personal decision to support
Jefferson. They decided to contribute
to research efforts that would
translate into advanced treatment
for patients with pancreatic cancer.

“It is truly the generosity
and the example set forth
by the Connollys that
will provide us with the
resources necessary to fight
this complicated disease”
The Connollys have pledged
$100,000 to support Jefferson’s
cutting edge clinical and investigative
work in pancreatic cancer and its
related diseases. Charles J. Yeo, MD,
Samuel D. Gross Professor and Chair
of Surgery, leads a multidisciplinary
team of surgeons, radiologists, and
gastroenterologists in the new
Jefferson Pancreatic, Biliary, and
Related Cancers Center. The
Connolly gift helps Dr. Yeo and the
Center pursue research discoveries
and gain momentum in the ongoing
fight against these diseases.

David Tichansky, MD has joined the

Division of General Surgery as the
Director of the Bariatric and Metabolic
Surgery Program. He specializes in totally
laparoscopic bariatric surgery and is
assisted by Alise Kuhl, CRNP-BC. For a
schedule of free patient seminars, go to
www.jeffersonhospital.org/bariatric

David Tichansky, MD

Susan Lanza-Jacoby, PhD was awarded a R21 NIH grant to study

different types of calorie restriction on the progression of PanIN
lesions to Pancreatic Ductal Adenocarcinoma (PDA).
Marianne and Charles Connelly’s generous contribution to the Jefferson
Pancreatic, Biliary, and Related Cancers Center is making individualized
treatment strategies a realistic possibility for future patients.

“We feel very fortunate for the
incredible experience I had at
Jefferson, most recently under Dr.
Yeo’s care,” says Marianne. “It is a
great gift that we can use my
situation to assist others. By
supporting Dr. Yeo’s research, we
are able to turn a negative personal
situation into something that
provides hope to many people.”
“It is truly the generosity and the
example set forth by the Connollys
that will provide us with the resources
necessary to fight this complicated
disease,” says Assistant Professor
Jonathan Brody, PhD, who runs a
laboratory devoted to pancreatic
cancer in the Division of Surgical
Research. “With the Connolly’s
commitment to our pancreatic group
here at Jefferson, we will be able to
explore the realistic possibility of
providing individualized and
enhanced treatment strategies to
patients with pancreatic cancer. In
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short, without these resources, many
of the group’s good ideas would never
be tested or eventually put into
practice with patients.”
While the Connolly’s generous
pledge has made ambitious basic and
translational pancreatic cancer
research possible at Jefferson, several
other fronts still require funding.
One such project is the Jefferson
Pancreas Tumor Registry, a
longitudinal study which aims to arm
researchers with a better
understanding of the familial
components of pancreatic cancer and
to identify environmental and
occupational exposures that may
increase an individual’s risk of
developing the disease.
For more information, or to
make a gift to the Department of
Surgery, please contact Lara Allan
Goldstein at 215-955-8797 or
Lara.AllanGoldstein@jefferson.edu.

620 Curtis Building
1015 Walnut Street
Philadelphia, PA 19107

Gerald A. Isenberg, MD and the Department of Surgery are co-

investigators in a NIH study of Wise-MD, a web based multimedia
teaching tool for surgical students created by New York University.
John Kairys, MD is a Co-Investigator on a Department of Defense

grant entitled, “3D Projection Environment for Molecular Design
and Surgical Simulation.” Eric Wickstrom, PhD, Professor of
Biochemistry and Molecular Biology, is the Principal Investigator.
Sharon Molotsky, RN, BSN, CCRC has been promoted to the newly

created position of Clinical Research Nurse Project Manager for the
Department of Surgery.
Paul J. DiMuzio, MD, PhD, was awarded first place for his

presentation, “Endothelial differentiation of adipose-derived
stem cells: How close have we really come?”, at the International
Federation for Adipose Therapeutics and Science (IFATS)
Conference, September 2009 in Toulouse, France.
May 31st marks the 25th anniversary of the first liver transplant
in the Delaware Valley performed at Jefferson. A celebratory
reception for liver transplant patients and families is planned for
Tuesday, May 5, 2009.
Save the Date: The Investiture of Cataldo Doria, MD, PhD
as the first Nicoletti Family Professor of Transplantation Surgery
will be held on June 17, 2009 at 4 p.m. in Connelly Auditorium,
Dorrance H. Hamilton Building. Please contact Lara Allan Goldstein
at 215-955-8797 if interested in attending.
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SurgicalSolutions
Minimally Invasive and Robotic General
Surgery an Option for More Patients

When Florence Jackson, 73, had some
difficulty swallowing her food one evening,
her husband insisted she see her doctor.
She mentioned it at her six-month checkup, and notes that years earlier she had
suffered from acid reflux, which is known
to be a possible cause of esophageal
cancer. A barium swallow test revealed an
obstruction in her esophagus.
In southern Delaware, where Florence
lives, there was no facility that could do an
endoscopic ultrasound. She was referred
to Jefferson, where she was treated by
Ernest (Gary) Rosato, MD, Director of the
General Surgery Division, and Associate
Professor Benny Weksler, MD, MBA, a
thoracic surgeon. She was diagnosed with
Stage 2A cancer of the esophagus, but the
team offered her an excellent treatment
plan. Prior to any surgery, Florence
underwent chemotherapy and radiation
therapy at the Tunnel Cancer Center in
Delaware to shrink the tumor as much as
possible. Then, at Jefferson, she underwent
a laparoscopic esophagectomy, which is
an innovative, minimally invasive surgery
with a relatively short recovery.
Jefferson is the only area hospital offering a
unique team approach which provides the
patient with the expertise of two surgeons
trained in minimally invasive surgery
(MIS). Dr. Weksler operates on the part of
the esophagus in the chest and Dr. Rosato
operates on the portion in the abdomen.
“My experience with Jefferson was none
other than outstanding,” says Florence.
“In addition to the kindness and respect
for me as an individual, it was a great
comfort to have such an experienced,
compassionate team with a successful track
record.” Florence’s stay in the hospital was
only 11 days, and she was pleased that she
was “back to normal” within just 10 days
of returning home.

Dr. Ernest (Gary) Rosato, Director of the General Surgery Division, and Florence Jackson are pleased
with her quick recovery and good prognosis following a minimally invasive esophagectomy to treat
Stage 2A esophageal cancer.

Jefferson is also the only hospital in the
Philadelphia region performing a high
volume of laparoscopic esophagectomies—
25 during 2008, and the Department
expects to double that number in 2009.
A study of those cases demonstrates a

Jefferson is also the only hospital
in the Philadelphia region
performing a high volume of
laparoscopic esophagectomies...
decrease in morbidity over open surgeries.
Dr. Rosato explains the benefits of this
procedure: “With conventional ‘open’
surgeries, the incisions are large and painful,
and the hospital stay is longer,” he says.
“Laparoscopic surgery results in shorter
recovery and patient hospitalization.”

Dr. Rosato also emphasizes Jefferson’s
commitment to the latest training and
technology. “We have steadily increased
our volume of minimal invasive surgeries
over the last four years,” he explains, “and
we are now training residents and a fellow
in the specialty.” Jooyeun Chung, MD,
the current Minimally Invasive Surgery
Fellow and a graduate of Jefferson’s
residency program, has already built
an impressive record with more than
30 minimally invasive surgeries for the
esophagus. “We are aggressively taking
the lead by developing one of the most
experienced MIS/GI/Thoracic capabilities
in Philadelphia,” says Dr. Rosato, “and
are setting the tone and pace for what will
become the future of general surgery.”
For more information about
Minimally Invasive Surgery visit:
www.jeffersonhospital.org/keyhole
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The Surgeon Speaks

Dr. Benny Weksler, who is Board
Certified in Surgery and Thoracic
Surgery, is a leader in the innovative
technique of robotic surgery. “Like
laparoscopic surgery, “Dr. Weksler
explains, “robotic surgery is done via
only a few small incisions. However,
instead of holding the surgical
instruments, the surgeon sits at a
control panel and utilizes robotic arms
to move the instruments.” He notes
that robotic surgery is far safer because
it offers greater precision, smaller
incisions, decreased blood loss, and less
pain for the patient.
The only robotic system approved by
the Food and Drug Administration is
the da Vinci® Surgical System, named
after the famous artist who invented the
first robot. “We are the only facility in
Philadelphia using robotic surgery for
thoracic operations,” says Dr. Weksler.
In 2008, Jefferson performed seven
operations utilizing this exciting new
technology. That number will increase
in 2009 and already includes four robotassisted esophagectomies for patients
like Florence Jackson.
Benny Weksler, MD, MBA

Director, Minimally Invasive and
Robotic Thoracic Surgery Program

Robert Solit, MD
Thomas Tulenko, PhD

Robert Neroni, Photography

Charles Yeo, MD

Information in Surgical Solutions is
not intended to provide advice on
personal medical matters or to
substitute for consultation with
a physician.

Lara Allan Goldstein
Flo Williams
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Clinical Integration

Overview

Charles J. Yeo, MD
Samuel D. Gross Professor and
Chair, Department of Surgery

The Spring of 2009 represents an exciting
time here in the Department of Surgery.
Despite the turbulent economic times,
our clinical footprint has grown nicely,
averaging a 5 to 12% increase per year for
the last three years. Newer programs such
as our minimally invasive esophagectomy
and pancreatectomy programs, our
bariatric surgery program, our mechanical
heart support program, and our thriving
acute care surgery (and intensivist)
program are examples of success stories.
We have received good news on the
research front. Our residents and faculty
just completed a very busy Fall and Winter,
when well over a dozen presentations were
made at national fora, such as the Southern
Surgical, the 4th Academic Surgical
Congress, the Southeastern Surgical, and
the American Hepato-Pancreato-Biliary
Association, amongst others. Additionally,
we are delighted to have recently been
notified of major grant awards to Drs.
Lanza-Jacoby and Tulenko, representing
NIH dollars into the Department. Our clinical
research has grown nicely, and the addition
of Sharon Molotsky, RN, BSN, CCRC as our
Clinical Research Nurse Project Manager
will do much to ensure the attention to
detail needed for our clinical trials.
My thanks go out to all members of the
Department for their enthusiasm, hard
work, clinical expertise and academic
performance over the last several years.
It has been wonderful to see Jefferson’s
stature rise amongst other academic
medical centers, as we have added faculty,
increased our clinical volumes, added
new clinical programs, and raised the
research profile (both for our basic science
researchers and for our clinicians).

https://jdc.jefferson.edu/jss/vol4/iss1/10

Residency Program graduates, Drs. Jay Jenoff and Niels Martin, have returned to Jefferson
as Assistant Professors in the Acute Care Surgery Division.

Acute Care Surgery Expands
its Faculty, Facilities & Research
New faculty, upgrades to the Intensive
Care Unit (ICU), and multiple new trials
and studies are just some of the changes
underway in the Acute Care Surgery
Division. The addition of Jay Jenoff, MD,
and Niels Martin, MD, brings the Division
team to seven faculty, strengthening its
intensivist program, which makes an
attending acute care surgeon available 24
hours a day, 7 days a week.
Drs. Jenoff and Martin recently joined
the Division after completing Fellowships in
Traumatology and Surgical Critical Care at
the Hospital of The University of
Pennsylvania. Dr. Jenoff, Assistant Professor
of Surgery and a 2005 graduate of the
Jefferson Surgery residency program, is
Board Certified in both surgery and critical
care medicine. Dr. Martin, a 2006 graduate
of Jefferson’s residency program is also
Board Certified in surgery and critical care
medicine and has been named the Associate
Program Director of Graduate Education.
As part of Jefferson’s commitment to
continually improving the care and
experience of patients, the hospital is
building a new, state-of-the-art ICU facility
in the Gibbon Building on Jefferson’s
Center City campus. Construction is
expected to be completed during this year
and will add to the existing ICU. The new
space will accommodate 34 beds, half of
which will be dedicated to surgical patients.

“This fully functional ICU will have the
most advanced technology, tools and
instruments available,” says Dr. Martin, “so
that we can respond to a patient’s needs,
from pre- and post-operative care to
bedside procedures, under ideal conditions
with the optimal equipment.”
“Like any professional team, each
member plays an important role,” says Dr.

Changing Lives Through Research
Zi-Xuan (Zoe) Wang, PhD

Jenoff, “and our two trauma nurse
practitioners, Alannah Ryan, CRNP, and
Catherine Gill-Preston, CRNP, are
absolutely invaluable to the doctors and
patients. Their case management skills,
skill level, and compassion for patients are
second-to-none.”
In addition to clinical priorities, the
Division is placing a renewed emphasis on
research and has recently undertaken
several clinical trials and studies. “A
number of these new studies make
Jefferson—and our Division in
particular—an exciting place to be right
now, a place to grow as a professional,”
says Dr. Martin. In trauma, for example,
the group is looking at new methods of
stabilization, prevention studies, and
resuscitation. Faculty members are also
studying abdominal wall outcomes and
developing new protocols, while working
with industry representatives on device
implementation. Research projects include
multidisciplinary collaborations with
Jefferson colleagues in rehabilitation and
orthopedics. Over the next 12–15 months
Division faculty will present findings at
multiple national academic meetings.

Zi-XuanWang, PhD, is an Assistant
Professor of Surgery, with a secondary
appointment in the Department
of Pathology, Anatomy, and Cell
Biology, where she is the Assistant
Director of the Clinical Microbiology
Laboratory. She joined Jefferson in
October 2008 after six years at the
Medical College of Georgia where
she was the Scientific Director of the
Molecular Diagnostics Laboratory.
What is the focus of your research?

Drs. Shayna Showalter, Matthew Rosen, L. Andrew Shirley, Nikolai Bildzukewicz,
Jennifer Sullivan and Timothy Williams have made impressive contributions to cancer
research at Jefferson as part of their surgical residency training.

Surgical Residents Make
Significant Contributions to
Ongoing Cancer Research

For more information about the Acute Care
Surgery Division, visit their new website at
www.jefferson.edu/acutecare

Please Welcome
Dr. Joshua Curtin in the
New Transplant Laboratory
Joshua Curtin, PhD, is a
research fellow in the lab
of Cataldo Doria, MD, PhD,
focusing on the regulation
of tumor cell growth and
division, primarily in the liver.
He examines how molecular
components of cellular signaling
pathways function to regulate
cell growth and cell death.
Dr. Curtin’s doctoral research studied the
actions of natural derivatives of Vitamin A
known as tumor cell differentiators. Derivatives
of Vitamin A are a class of compounds known
as retinoids, which have been shown to
prevent the unchecked division of cancer
cells. “Although traditional chemotherapies
kill both the mutated cancer cells and the
healthy normal cells,” Dr. Curtin explains,
“this treatment stops only the cancer cells
from dividing.”

On the Job

Dr. Curtin has coupled his expertise as
a cancer biologist with his experience
as a post-doctoral fellow in liver biology.
“The ultimate goal,” he explains, “is to
translate discovery in the lab into improved
clinical treatment for patients suffering
from liver cancer.”
To read more about this research, go to
www.jeffersonhospital.org/transplant
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The Department of Surgery’s research
efforts have expanded greatly in recent
years as evidenced by the breadth and
depth of resident research projects.
Dr. L. Andrew Shirley spent two years
in the laboratory and was the Principal
Investigator of a study analyzing the role of
the Dachshund (DACH1) cell fate
determination pathway in various cancer
types, including breast, prostate, colorectal,
and pancreatic cancers. The study, funded
by a Radiation Therapy Oncology Group
Translational Research Program seed
grant, was conducted under the
mentorship of Richard Pestell, MD, PhD,
Director of the Kimmel Cancer Center. Dr.
Shirley presented the findings at the 3rd
Annual Academic Surgical Congress and
in four peer-reviewed articles.
Jonathan Brody, PhD, a specialist in
pancreatic cancer research has mentored
several residents in his laboratory.
Dr. Shayna Showalter explored targets
in pancreatic cancer to develop novel
therapeutic strategies and examined the
effect of naturally occurring Vitamin K on
pancreatic cancer cells. She found that

Vitamin K actually inhibits pancreatic
cancer cell growth. Dr. Showalter also used
novel nanoparticle technology to deliver
diphtheria toxin specifically to pancreatic
cancer cells, therefore killing the cancer
cells without effecting the growth of
normal, noncancer cells. To date, she has
presented the findings at three meetings,
including the American Association for
Cancer Research Annual Meeting, and in
three peer-reviewed articles.
Also under Dr. Brody’s mentorship,
Dr. Timothy Williams investigated the
tumor suppressor protein pp32 and its role
in pancreatic tumor development. The
research established that pp32 is low or
absent in poorly differentiated pancreatic
cancer, it suppresses tumor growth when
its expression is restored, and impacts the
response of cancer cells to certain
chemotherapy drugs commonly used to
treat pancreatic cancer. To date, Dr.
Williams has published three peerreviewed publications on this research,
presented posters at three meetings and
shares the Award for Best Research
Presentation in the Department of Surgery.

My passion is personalized medicine:
to find out how and why certain
therapies/medicines do or do
not work and then to develop a
customized approach to enhance a
patient’s treatment. Since people can
metabolize or respond to medicines
in various ways, genetic analysis can
predict a certain patient’s response, so
that therapeutics can be administered
and dosed optimally.
How do you use technology in
your work?

DNA sequencing and gene chips
have made testing individuals feasible.
We characterize specific aspects of
cancer and host genomes to predict
whether a drug will be effective
or whether serious side effects
Dr. Nikolai Bildzukewicz is continuing
the work established by Dr. Williams on
the role of pp32 in a drug resistance
pathway. However, his primary research
focuses on Poly(ADP Ribose) Polymerase1 (PARP-1), an enzyme found within the
cell nucleus that serves many cellular
functions including repair of damaged
DNA. In collaboration with John Pascal,
PhD, Assistant Professor of Biochemistry
and Molecular Biology, Dr. Bildzukewicz
is working with both normal and mutant
forms of the enzyme in pancreatic cancer
cells. His findings include the concept of
using novel agents, PARP-inhibitors, to
sensitize pancreatic cancer cells to
platinum-based FDA-approved drugs.
This work provides the proof-of-principle
data for a proposed clinical trial. Dr.
Bildzukewicz presented the initial findings
to the Philadelphia Academy of Surgery
meeting in February 2008.
In Dr. Susan Lanza-Jacoby’s laboratory,
Dr. Matthew Rosen is studying the effect
of Nexrutine, a natural Cox-2 inhibitor on

will emerge. Characterization of
mutations in the patient’s genome can
predict drug resistance and provide a
personalized approach.
What motivates you on a day-today basis?

As a scientist, I am dedicated to
improving the health of human
beings and I especially enjoy working
with the surgical faculty on pancreatic
cancer and translational research.
As a team, our analytical skills and
emerging technologies have pushed
us to the leading edge of diagnostics.
Future collaborations with other
Jefferson researchers will further
advance our progress and ultimately
improve medicine.

pancreatic cancer cells, and the
relationship of sirtuin (a protein involved
in improving health during calorie
restriction) to pancreatic cancer. Dr.
Rosen has already presented findings at
two meetings including the American
Association of Cancer Research. Dr.
Rosen is also the recipient of the Arnold
P. Gold Foundation Humanism and
Excellence in Teaching Award.
In Dr. Hwyda Arafat’s laboratory,
Dr. Jennifer Sullivan is analyzing how
nictotine exposure contributes to the
aggressive nature of pancreatic cancer.
Her research focuses on the expression of
a protein, Osteopontin-C, which appears
to be increased in patients with pancreatic
cancer, especially those with a history of
smoking. This protein could be a potential
target for future therapy. Dr. Sullivan
recently presented her data at the
Academic Surgical Congress and a
manuscript has been accepted for
publication in Surgery.
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Overview

Charles J. Yeo, MD
Samuel D. Gross Professor and
Chair, Department of Surgery

The Spring of 2009 represents an exciting
time here in the Department of Surgery.
Despite the turbulent economic times,
our clinical footprint has grown nicely,
averaging a 5 to 12% increase per year for
the last three years. Newer programs such
as our minimally invasive esophagectomy
and pancreatectomy programs, our
bariatric surgery program, our mechanical
heart support program, and our thriving
acute care surgery (and intensivist)
program are examples of success stories.
We have received good news on the
research front. Our residents and faculty
just completed a very busy Fall and Winter,
when well over a dozen presentations were
made at national fora, such as the Southern
Surgical, the 4th Academic Surgical
Congress, the Southeastern Surgical, and
the American Hepato-Pancreato-Biliary
Association, amongst others. Additionally,
we are delighted to have recently been
notified of major grant awards to Drs.
Lanza-Jacoby and Tulenko, representing
NIH dollars into the Department. Our clinical
research has grown nicely, and the addition
of Sharon Molotsky, RN, BSN, CCRC as our
Clinical Research Nurse Project Manager
will do much to ensure the attention to
detail needed for our clinical trials.
My thanks go out to all members of the
Department for their enthusiasm, hard
work, clinical expertise and academic
performance over the last several years.
It has been wonderful to see Jefferson’s
stature rise amongst other academic
medical centers, as we have added faculty,
increased our clinical volumes, added
new clinical programs, and raised the
research profile (both for our basic science
researchers and for our clinicians).

Residency Program graduates, Drs. Jay Jenoff and Niels Martin, have returned to Jefferson
as Assistant Professors in the Acute Care Surgery Division.

Acute Care Surgery Expands
its Faculty, Facilities & Research
New faculty, upgrades to the Intensive
Care Unit (ICU), and multiple new trials
and studies are just some of the changes
underway in the Acute Care Surgery
Division. The addition of Jay Jenoff, MD,
and Niels Martin, MD, brings the Division
team to seven faculty, strengthening its
intensivist program, which makes an
attending acute care surgeon available 24
hours a day, 7 days a week.
Drs. Jenoff and Martin recently joined
the Division after completing Fellowships in
Traumatology and Surgical Critical Care at
the Hospital of The University of
Pennsylvania. Dr. Jenoff, Assistant Professor
of Surgery and a 2005 graduate of the
Jefferson Surgery residency program, is
Board Certified in both surgery and critical
care medicine. Dr. Martin, a 2006 graduate
of Jefferson’s residency program is also
Board Certified in surgery and critical care
medicine and has been named the Associate
Program Director of Graduate Education.
As part of Jefferson’s commitment to
continually improving the care and
experience of patients, the hospital is
building a new, state-of-the-art ICU facility
in the Gibbon Building on Jefferson’s
Center City campus. Construction is
expected to be completed during this year
and will add to the existing ICU. The new
space will accommodate 34 beds, half of
which will be dedicated to surgical patients.

“This fully functional ICU will have the
most advanced technology, tools and
instruments available,” says Dr. Martin, “so
that we can respond to a patient’s needs,
from pre- and post-operative care to
bedside procedures, under ideal conditions
with the optimal equipment.”
“Like any professional team, each
member plays an important role,” says Dr.

Changing Lives Through Research
Jenoff, “and our two trauma nurse
practitioners, Alannah Ryan, CRNP, and
Catherine Gill-Preston, CRNP, are
absolutely invaluable to the doctors and
patients. Their case management skills,
skill level, and compassion for patients are
second-to-none.”
In addition to clinical priorities, the
Division is placing a renewed emphasis on
research and has recently undertaken
several clinical trials and studies. “A
number of these new studies make
Jefferson—and our Division in
particular—an exciting place to be right
now, a place to grow as a professional,”
says Dr. Martin. In trauma, for example,
the group is looking at new methods of
stabilization, prevention studies, and
resuscitation. Faculty members are also
studying abdominal wall outcomes and
developing new protocols, while working
with industry representatives on device
implementation. Research projects include
multidisciplinary collaborations with
Jefferson colleagues in rehabilitation and
orthopedics. Over the next 12–15 months
Division faculty will present findings at
multiple national academic meetings.
For more information about the Acute Care
Surgery Division, visit their new website at
www.jefferson.edu/acutecare

Please Welcome
Dr. Joshua Curtin in the
New Transplant Laboratory
Joshua Curtin, PhD, is a
research fellow in the lab
of Cataldo Doria, MD, PhD,
focusing on the regulation
of tumor cell growth and
division, primarily in the liver.
He examines how molecular
components of cellular signaling
pathways function to regulate
cell growth and cell death.
Dr. Curtin’s doctoral research studied the
actions of natural derivatives of Vitamin A
known as tumor cell differentiators. Derivatives
of Vitamin A are a class of compounds known
as retinoids, which have been shown to
prevent the unchecked division of cancer
cells. “Although traditional chemotherapies
kill both the mutated cancer cells and the
healthy normal cells,” Dr. Curtin explains,
“this treatment stops only the cancer cells
from dividing.”

Dr. Curtin has coupled his expertise as
a cancer biologist with his experience
as a post-doctoral fellow in liver biology.
“The ultimate goal,” he explains, “is to
translate discovery in the lab into improved
clinical treatment for patients suffering
from liver cancer.”
To read more about this research, go to
www.jeffersonhospital.org/transplant

On the Job
Zi-Xuan (Zoe) Wang, PhD
Zi-XuanWang, PhD, is an Assistant
Professor of Surgery, with a secondary
appointment in the Department
of Pathology, Anatomy, and Cell
Biology, where she is the Assistant
Director of the Clinical Microbiology
Laboratory. She joined Jefferson in
October 2008 after six years at the
Medical College of Georgia where
she was the Scientific Director of the
Molecular Diagnostics Laboratory.
What is the focus of your research?

Drs. Shayna Showalter, Matthew Rosen, L. Andrew Shirley, Nikolai Bildzukewicz,
Jennifer Sullivan and Timothy Williams have made impressive contributions to cancer
research at Jefferson as part of their surgical residency training.

Surgical Residents Make
Significant Contributions to
Ongoing Cancer Research
The Department of Surgery’s research
efforts have expanded greatly in recent
years as evidenced by the breadth and
depth of resident research projects.
Dr. L. Andrew Shirley spent two years
in the laboratory and was the Principal
Investigator of a study analyzing the role of
the Dachshund (DACH1) cell fate
determination pathway in various cancer
types, including breast, prostate, colorectal,
and pancreatic cancers. The study, funded
by a Radiation Therapy Oncology Group
Translational Research Program seed
grant, was conducted under the
mentorship of Richard Pestell, MD, PhD,
Director of the Kimmel Cancer Center. Dr.
Shirley presented the findings at the 3rd
Annual Academic Surgical Congress and
in four peer-reviewed articles.
Jonathan Brody, PhD, a specialist in
pancreatic cancer research has mentored
several residents in his laboratory.
Dr. Shayna Showalter explored targets
in pancreatic cancer to develop novel
therapeutic strategies and examined the
effect of naturally occurring Vitamin K on
pancreatic cancer cells. She found that

Vitamin K actually inhibits pancreatic
cancer cell growth. Dr. Showalter also used
novel nanoparticle technology to deliver
diphtheria toxin specifically to pancreatic
cancer cells, therefore killing the cancer
cells without effecting the growth of
normal, noncancer cells. To date, she has
presented the findings at three meetings,
including the American Association for
Cancer Research Annual Meeting, and in
three peer-reviewed articles.
Also under Dr. Brody’s mentorship,
Dr. Timothy Williams investigated the
tumor suppressor protein pp32 and its role
in pancreatic tumor development. The
research established that pp32 is low or
absent in poorly differentiated pancreatic
cancer, it suppresses tumor growth when
its expression is restored, and impacts the
response of cancer cells to certain
chemotherapy drugs commonly used to
treat pancreatic cancer. To date, Dr.
Williams has published three peerreviewed publications on this research,
presented posters at three meetings and
shares the Award for Best Research
Presentation in the Department of Surgery.
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My passion is personalized medicine:
to find out how and why certain
therapies/medicines do or do
not work and then to develop a
customized approach to enhance a
patient’s treatment. Since people can
metabolize or respond to medicines
in various ways, genetic analysis can
predict a certain patient’s response, so
that therapeutics can be administered
and dosed optimally.
How do you use technology in
your work?

DNA sequencing and gene chips
have made testing individuals feasible.
We characterize specific aspects of
cancer and host genomes to predict
whether a drug will be effective
or whether serious side effects
Dr. Nikolai Bildzukewicz is continuing
the work established by Dr. Williams on
the role of pp32 in a drug resistance
pathway. However, his primary research
focuses on Poly(ADP Ribose) Polymerase1 (PARP-1), an enzyme found within the
cell nucleus that serves many cellular
functions including repair of damaged
DNA. In collaboration with John Pascal,
PhD, Assistant Professor of Biochemistry
and Molecular Biology, Dr. Bildzukewicz
is working with both normal and mutant
forms of the enzyme in pancreatic cancer
cells. His findings include the concept of
using novel agents, PARP-inhibitors, to
sensitize pancreatic cancer cells to
platinum-based FDA-approved drugs.
This work provides the proof-of-principle
data for a proposed clinical trial. Dr.
Bildzukewicz presented the initial findings
to the Philadelphia Academy of Surgery
meeting in February 2008.
In Dr. Susan Lanza-Jacoby’s laboratory,
Dr. Matthew Rosen is studying the effect
of Nexrutine, a natural Cox-2 inhibitor on

will emerge. Characterization of
mutations in the patient’s genome can
predict drug resistance and provide a
personalized approach.
What motivates you on a day-today basis?

As a scientist, I am dedicated to
improving the health of human
beings and I especially enjoy working
with the surgical faculty on pancreatic
cancer and translational research.
As a team, our analytical skills and
emerging technologies have pushed
us to the leading edge of diagnostics.
Future collaborations with other
Jefferson researchers will further
advance our progress and ultimately
improve medicine.

pancreatic cancer cells, and the
relationship of sirtuin (a protein involved
in improving health during calorie
restriction) to pancreatic cancer. Dr.
Rosen has already presented findings at
two meetings including the American
Association of Cancer Research. Dr.
Rosen is also the recipient of the Arnold
P. Gold Foundation Humanism and
Excellence in Teaching Award.
In Dr. Hwyda Arafat’s laboratory,
Dr. Jennifer Sullivan is analyzing how
nictotine exposure contributes to the
aggressive nature of pancreatic cancer.
Her research focuses on the expression of
a protein, Osteopontin-C, which appears
to be increased in patients with pancreatic
cancer, especially those with a history of
smoking. This protein could be a potential
target for future therapy. Dr. Sullivan
recently presented her data at the
Academic Surgical Congress and a
manuscript has been accepted for
publication in Surgery.
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Survivor Turned
Supporter
Diagnosed with and successfully
treated for breast cancer at Jefferson
in 1984, Marianne Connolly
returned when faced with a potential
diagnosis of pancreatic cancer in
2005. Feeling blessed by her
fortunate outcome and access to
excellent medical care, Marianne
and her husband Charles made a
very personal decision to support
Jefferson. They decided to contribute
to research efforts that would
translate into advanced treatment
for patients with pancreatic cancer.

“It is truly the generosity
and the example set forth
by the Connollys that
will provide us with the
resources necessary to fight
this complicated disease”
The Connollys have pledged
$100,000 to support Jefferson’s
cutting edge clinical and investigative
work in pancreatic cancer and its
related diseases. Charles J. Yeo, MD,
Samuel D. Gross Professor and Chair
of Surgery, leads a multidisciplinary
team of surgeons, radiologists, and
gastroenterologists in the new
Jefferson Pancreatic, Biliary, and
Related Cancers Center. The
Connolly gift helps Dr. Yeo and the
Center pursue research discoveries
and gain momentum in the ongoing
fight against these diseases.

SurgicalSolutions

News in Brief

Those Who Give
David Tichansky, MD has joined the

Division of General Surgery as the
Director of the Bariatric and Metabolic
Surgery Program. He specializes in totally
laparoscopic bariatric surgery and is
assisted by Alise Kuhl, CRNP-BC. For a
schedule of free patient seminars, go to
www.jeffersonhospital.org/bariatric

Minimally Invasive and Robotic General
Surgery an Option for More Patients

David Tichansky, MD

Susan Lanza-Jacoby, PhD was awarded a R21 NIH grant to study

different types of calorie restriction on the progression of PanIN
lesions to Pancreatic Ductal Adenocarcinoma (PDA).
Marianne and Charles Connelly’s generous contribution to the Jefferson
Pancreatic, Biliary, and Related Cancers Center is making individualized
treatment strategies a realistic possibility for future patients.

“We feel very fortunate for the
incredible experience I had at
Jefferson, most recently under Dr.
Yeo’s care,” says Marianne. “It is a
great gift that we can use my
situation to assist others. By
supporting Dr. Yeo’s research, we
are able to turn a negative personal
situation into something that
provides hope to many people.”
“It is truly the generosity and the
example set forth by the Connollys
that will provide us with the resources
necessary to fight this complicated
disease,” says Assistant Professor
Jonathan Brody, PhD, who runs a
laboratory devoted to pancreatic
cancer in the Division of Surgical
Research. “With the Connolly’s
commitment to our pancreatic group
here at Jefferson, we will be able to
explore the realistic possibility of
providing individualized and
enhanced treatment strategies to
patients with pancreatic cancer. In

SurgicalSolutions
Jefferson Department of Surgery
620 Curtis Building
1015 Walnut Street
Philadelphia, PA 19107

www.JeffersonHospital.org/surgery

short, without these resources, many
of the group’s good ideas would never
be tested or eventually put into
practice with patients.”
While the Connolly’s generous
pledge has made ambitious basic and
translational pancreatic cancer
research possible at Jefferson, several
other fronts still require funding.
One such project is the Jefferson
Pancreas Tumor Registry, a
longitudinal study which aims to arm
researchers with a better
understanding of the familial
components of pancreatic cancer and
to identify environmental and
occupational exposures that may
increase an individual’s risk of
developing the disease.
For more information, or to
make a gift to the Department of
Surgery, please contact Lara Allan
Goldstein at 215-955-8797 or
Lara.AllanGoldstein@jefferson.edu.

620 Curtis Building
1015 Walnut Street
Philadelphia, PA 19107

Gerald A. Isenberg, MD and the Department of Surgery are co-

When Florence Jackson, 73, had some
difficulty swallowing her food one evening,
her husband insisted she see her doctor.
She mentioned it at her six-month checkup, and notes that years earlier she had
suffered from acid reflux, which is known
to be a possible cause of esophageal
cancer. A barium swallow test revealed an
obstruction in her esophagus.

investigators in a NIH study of Wise-MD, a web based multimedia
teaching tool for surgical students created by New York University.
John Kairys, MD is a Co-Investigator on a Department of Defense

grant entitled, “3D Projection Environment for Molecular Design
and Surgical Simulation.” Eric Wickstrom, PhD, Professor of
Biochemistry and Molecular Biology, is the Principal Investigator.
Sharon Molotsky, RN, BSN, CCRC has been promoted to the newly

In southern Delaware, where Florence
lives, there was no facility that could do an
endoscopic ultrasound. She was referred
to Jefferson, where she was treated by
Ernest (Gary) Rosato, MD, Director of the
General Surgery Division, and Associate
Professor Benny Weksler, MD, MBA, a
thoracic surgeon. She was diagnosed with
Stage 2A cancer of the esophagus, but the
team offered her an excellent treatment
plan. Prior to any surgery, Florence
underwent chemotherapy and radiation
therapy at the Tunnel Cancer Center in
Delaware to shrink the tumor as much as
possible. Then, at Jefferson, she underwent
a laparoscopic esophagectomy, which is
an innovative, minimally invasive surgery
with a relatively short recovery.

created position of Clinical Research Nurse Project Manager for the
Department of Surgery.
Paul J. DiMuzio, MD, PhD, was awarded first place for his

presentation, “Endothelial differentiation of adipose-derived
stem cells: How close have we really come?”, at the International
Federation for Adipose Therapeutics and Science (IFATS)
Conference, September 2009 in Toulouse, France.
May 31st marks the 25th anniversary of the first liver transplant
in the Delaware Valley performed at Jefferson. A celebratory
reception for liver transplant patients and families is planned for
Tuesday, May 5, 2009.
Save the Date: The Investiture of Cataldo Doria, MD, PhD
as the first Nicoletti Family Professor of Transplantation Surgery
will be held on June 17, 2009 at 4 p.m. in Connelly Auditorium,
Dorrance H. Hamilton Building. Please contact Lara Allan Goldstein
at 215-955-8797 if interested in attending.

Jefferson is the only area hospital offering a
unique team approach which provides the
patient with the expertise of two surgeons
trained in minimally invasive surgery
(MIS). Dr. Weksler operates on the part of
the esophagus in the chest and Dr. Rosato
operates on the portion in the abdomen.
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“My experience with Jefferson was none
other than outstanding,” says Florence.
“In addition to the kindness and respect
for me as an individual, it was a great
comfort to have such an experienced,
compassionate team with a successful track
record.” Florence’s stay in the hospital was
only 11 days, and she was pleased that she
was “back to normal” within just 10 days
of returning home.
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Jefferson is also the only hospital in the
Philadelphia region performing a high
volume of laparoscopic esophagectomies—
25 during 2008, and the Department
expects to double that number in 2009.
A study of those cases demonstrates a

Jefferson is also the only hospital
in the Philadelphia region
performing a high volume of
laparoscopic esophagectomies...
decrease in morbidity over open surgeries.
Dr. Rosato explains the benefits of this
procedure: “With conventional ‘open’
surgeries, the incisions are large and painful,
and the hospital stay is longer,” he says.
“Laparoscopic surgery results in shorter
recovery and patient hospitalization.”

Dr. Rosato also emphasizes Jefferson’s
commitment to the latest training and
technology. “We have steadily increased
our volume of minimal invasive surgeries
over the last four years,” he explains, “and
we are now training residents and a fellow
in the specialty.” Jooyeun Chung, MD,
the current Minimally Invasive Surgery
Fellow and a graduate of Jefferson’s
residency program, has already built
an impressive record with more than
30 minimally invasive surgeries for the
esophagus. “We are aggressively taking
the lead by developing one of the most
experienced MIS/GI/Thoracic capabilities
in Philadelphia,” says Dr. Rosato, “and
are setting the tone and pace for what will
become the future of general surgery.”
For more information about
Minimally Invasive Surgery visit:
www.jeffersonhospital.org/keyhole
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The Surgeon Speaks

Dr. Benny Weksler, who is Board
Certified in Surgery and Thoracic
Surgery, is a leader in the innovative
technique of robotic surgery. “Like
laparoscopic surgery, “Dr. Weksler
explains, “robotic surgery is done via
only a few small incisions. However,
instead of holding the surgical
instruments, the surgeon sits at a
control panel and utilizes robotic arms
to move the instruments.” He notes
that robotic surgery is far safer because
it offers greater precision, smaller
incisions, decreased blood loss, and less
pain for the patient.
The only robotic system approved by
the Food and Drug Administration is
the da Vinci® Surgical System, named
after the famous artist who invented the
first robot. “We are the only facility in
Philadelphia using robotic surgery for
thoracic operations,” says Dr. Weksler.
In 2008, Jefferson performed seven
operations utilizing this exciting new
technology. That number will increase
in 2009 and already includes four robotassisted esophagectomies for patients
like Florence Jackson.
Benny Weksler, MD, MBA

Director, Minimally Invasive and
Robotic Thoracic Surgery Program

Robert Solit, MD
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Dr. Ernest (Gary) Rosato, Director of the General Surgery Division, and Florence Jackson are pleased
with her quick recovery and good prognosis following a minimally invasive esophagectomy to treat
Stage 2A esophageal cancer.
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